Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom))
Cleverly, Ann (Eli Lilly and Company (United Kingdom))
Desaiah, Durisala (Eli Lilly and Company (USA))
Azaro, Analía (Hospital Universitari Vall d'Hebron)
Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia)
Braña, Irene (Hospital Universitari Vall d'Hebron)
Sicart, Elisabet (Hospital Universitari Vall d'Hebron)
Miles, Colin (Eli Lilly and Company (United Kingdom))
Lahn, Michael M.. (Eli Lilly and Company (USA))
Mitchell, Malcolm I (Eli Lilly and Company (USA))
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona

Date:	2016
Abstract:	Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. The secondary objective was to report the safety profile after a single dose of the three formulations. Patients with advanced or metastatic cancer were enrolled into this single-center, 3-period, 6-sequence crossover study. Patients were assigned sequentially to 1 of 6 sequences in blocks of 6 to ensure that all 6 sequences have the same number of completers. A patient entering a sequence received a different galunisertib formulation as a single 150 mg dose orally during each of the 3 periods. Each period was separated from the next by a washout interval of at least 48 hours. Pharmacokinetic (PK) parameters, including area under curve (AUC) and C, were computed using standard non-compartmentalized methods of analysis. For comparison of exposures between formulations, log-transformed AUC and C values were analyzed using a linear mixed-effects model. Safety assessments included adverse event monitoring, physical examinations, and laboratory tests. Of the 14 patients who entered and completed the study, 13 patients were included in the final statistical analysis. AUC(0-t), AUC(0-48 h), and AUC(0-∞) for the RC formulations and the HSWG formulation were similar. C was reduced by approximately 22% and t was longer by at least 1. 00 h for the RCD and RCS formulations compared with the HSWG formulation. The RC formulations demonstrated a safety profile after a single dose similar to the HSWG formulation. In this relative bioavailability study comparing galunisertib formulations after a single dose, RCD and RCS formulations had similar exposure and safety profile compared with the HSWG formulation.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	LY2157299 ; Transforming growth factor beta ; Area under curve ; Biological availability ; Half-life ; Pharmacokinetics ; Neoplasms ; Adverse drug event
Published in:	Drugs in Context, Vol. 5 (December 2016) , art. 201303, ISSN 1740-4398

DOI: 10.7573/dic.212303
PMID: 27990167

8 p, 500.8 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles